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We are pleased to inform our readership and authors about
an improved new impact factor for the European Archives
of Psychiatry and Clinical Neuroscience in 2010. The
journal managed raising its impact factor from 2.747 to
3.637 and herewith achieving the best result in the history
of EAPCN. Hereby, our journal’s position ascends from
position 59 to 40 in the ranking of Clinical Neurological
journals and from 47 to 31 in the ranking of Psychiatric
journals. We would like to thank all our authors and
reviewers for their valuable contributions, allowing such an
increase in quality. Further reasons for the rise of our
impact factor probably are based upon the high quality of
reviewers as leading experts in their ﬁelds and the focus on
original manuscripts with topics related to neurobiological
key aspects. 2008 and 2009, the years determining the 2010
impact factor, are characterized by frequent citations in
several issues. Some examples of well-cited manuscripts
referring to genetic backgrounds of psychiatric diseases are
e.g., Maier et al. [1], Kishi et al. [2], and Gonda et al. [3],
for genetic imaging Kircher et al. [4] gained remarkable
attention, likewise D’Souza et al. [5] for effects of envi-
ronmental factors and Koenen et al. [6] and Grisham et al.
[7] for gene-environment interactions. Of substantiated
scientiﬁc interest obviously are well-cited studies on psy-
chopharmacological treatment options and their relation-
ship to neurobiology (Mo ¨ller et al. [8], Mo ¨ller [9, 10],
Leyhe et al. [11], Bauer et al. [12], Mendes et al. [13],
Ro ¨sler et al. [14]). This also applies to the neurobiological
background of psychiatric diseases, including brain imag-
ing, molecular, proteomic, and biochemical studies (Mu ¨ller
and Schwarz [15], Scherk et al. [16], Martins-de-Souza
et al. [17], Galve-Roperh et al. [18], Zanetti et al. [19],
Hoeppner et al. [20]).
This success highly motivates our EAPCN team to
maintain a platform for neuropsychiatric publications
comprising high class methodology in the European
catchment area. Respectively, our future issues will focus
on multifaceted neurobiological aspects and original work,
while we intend to refrain from publishing case reports and
pure validations of psychiatric rating scales. In accordance
to this policy, in the September issue, we set our focus on
perinatal complications and their interaction with genetic
factors in a sibling design in anorexia nervosa by Favaro
et al. [21] as well as lifetime cannabis use as a predictor of
earlier age of onset in bipolar disorder by Lagerberg et al.
[22]. These studies extend our knowledge on environ-
mental factors and gene-environment interactions in major
psychiatric diseases. In addition, in a voxel-based mor-
phometric study, Molina et al. [23] rely on brain morpho-
logical correlates of atypical antipsychotics and ﬁnd
several brain regions related to clinical improvement or
non-response. The paper conﬁrms previous investigations
in which striatal size has been referred to action of anti-
psychotics and extends the knowledge to other brain
regions such as insular cortex. A further study of Correll
et al. [24] on aspects of side effects of second generation
antipsychotics in patients without metabolic syndrome
addresses aspects of obesity as a frequent adverse effect of
treatment. To complete the complex picture of treatment
strategies, one study of Kristensen et al. [25] focuses
on electroconvulsive therapy in treatment-refractory
P. Falkai (&)
Department of Psychiatry and Psychotherapy,
University of Go ¨ttingen, Von-Siebold-Str. 5,
37075 Go ¨ttingen, Germany
e-mail: pfalkai@gwdg.de
H.-J. Mo ¨ller
Psychiatry Hospital, Ludwigs-Maximilians-University Munich,
Nussbaumstr.7, 80336 Munich, Germany
123
Eur Arch Psychiatry Clin Neurosci (2011) 261:387–389
DOI 10.1007/s00406-011-0237-zschizophrenia. In an interesting FDG-PET study of Pol-
janski et al. [26] in a large cohort of patients with fronto-
temporal lobar degeneration compared to patients with
Alzheimer’s disease or mild cognitive impairment, a sen-
sitivity of FDG-PET of 89% could be reached for correct
diagnosis of patients with frontotemporal lobar degenera-
tion. Cognitive impairments are central symptoms in psy-
chiatric patients, often leading to social deﬁcits and burden
of the disease. Using a neuropsychological test battery in a
population-based sample of patients with major psychiatric
diseases, Tuulio-Henriksson et al. [27] found mainly
patients with schizophrenia and non-affective psychoses
impaired, suggesting that with respect to this domain, these
patients are more severely affected than patients with
affective disorders.
We hope that these aspects are of interest for our
readership and are looking forward receiving further like-
wise interesting manuscripts in 2011.
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